Discontinuation Syndrome in SSRI Treatment

Introduction to Discontinuation Syndrome

Citalopram, sertraline, and especially paroxetine are known to cause discontinuation syndrome when doses are missed or stopped abruptly, according to the American Academy of Child and Adolescent Psychiatry 1

The American Academy of Child and Adolescent Psychiatry and the Mayo Clinic recommend tapering SSRI doses by no more than 10% of the current dose every 1-2 weeks for shorter-acting SSRIs like citalopram 1, 3
For patients on citalopram, this means reducing the dose by 0.75 mg (10%) every 1-2 weeks, starting from 7.5 mg, as suggested by the Mayo Clinic 3
Each new dose should be 90% of the previous dose, not a straight line to zero, as recommended by the Mayo Clinic 3

Clonidine 0.1 mg 1-2 times a day can treat discontinuation symptoms without stopping the taper, according to the Mayo Clinic 3
Very small dose reductions (5% instead of 10%) can reduce anxiety and build trust, as suggested by the Mayo Clinic 3

Buspirone 5 mg 2 times a day can be safely added to citalopram for extra anxiety control, as recommended by the Praxis Medical Insights 2
Buspirone requires 2-4 weeks for therapeutic effect and should be titrated with 5 mg every 5-7 days up to 15-30 mg/day divided into 2 doses, according to the Praxis Medical Insights 2

Abrupt cessation or large dose reductions are unacceptable medical care, except in extreme cases, as stated by the Mayo Clinic 3
Sudden stopping of SSRIs is no more acceptable than sudden stopping of antihypertensives, according to the Mayo Clinic and the American Academy of Child and Adolescent Psychiatry 1, 3

During tapering, weekly assessment of anxiety symptoms, agitation levels, and other discontinuation symptoms is essential, as recommended by the Praxis Medical Insights 2
Cognitive function should be monitored to rule out decline, according to the Praxis Medical Insights 2

After slow, voluntary reduction of long-term SSRI dosing, patients can experience improvements in function, quality of life, anxiety, and mood without worsening pain or with reduced pain levels, as reported by the MMWR Recommendations and Reports 4